Consistent with those studies mentioned later, we observed that when DG was supplemented, HFD mice were characterized by several obesity-related metabolic improvements including lower serum glucose and insulin levels, increased insulin sensitivity, few hepatic steatosis and resistance to weight gain by ileal FXR-FGF15 signaling inhibition. The gene discussed is INS; the disease is Hepatic steatosis.